目的 探討心血寧片聯(lián)合纈沙坦氫氯噻嗪治療原發(fā)性高血壓的臨床療效。方法 選取2021年3月—2022年3月上海交通大學醫(yī)學院附屬新華醫(yī)院收治的116例原發(fā)性高血壓患者，按照隨機數(shù)字表法分為對照組和治療組，每組各58例。對照組口服纈沙坦氫氯噻嗪片，1片/次，1次/d。治療組在對照組治療基礎上口服心血寧片，4片/次，3次/d。兩組療程12周。觀察兩組療效及主要癥狀消失率。比較治療前后兩組診室血壓[收縮壓（SBP）、舒張壓（DBP）]，24 h動態(tài)血壓指標及杜氏高血壓生活質(zhì)量量表、世界衛(wèi)生組織生活質(zhì)量測定簡表（WHOQOL-BREF）評分。結(jié)果 治療后，治療組總有效率是96.55%，較對照組86.21%顯著提高（P＜0.05）。治療后，兩組診室SBP、DBP均較治療前顯著下降（P＜0.05）；治療后，治療組診室SBP、DBP低于對照組（P＜0.05）。治療后，兩組24 h SBP、24 h DBP、白天SBP（dSBP）、白天DBP（dDBP）、夜間SBP（nSBP）、夜間DBP（nDBP）24 h平均動脈壓（24 h MAP）、24 h SBP變異系數(shù)（24 h SBPCV）、24 h DBP變異系數(shù)（24 h DBPCV）均較治療前顯著降低（P＜0.05）；且以治療組降低更顯著（P＜0.05）。治療后，治療組頭暈目眩、頭痛、胸悶的消失率分別是94.83%、89.66%、79.31%，均顯著高于對照組的86.21%、75.86%、62.07%（P＜0.05）。治療后，兩組杜氏高血壓生活質(zhì)量量表評分、WHOQOL-BREF評分均顯著增加（P＜0.05），且治療后，治療組杜氏高血壓生活質(zhì)量量表評分、WHOQOL-BREF評分均高于對照組（P＜0.05）。結(jié)論 心血寧片聯(lián)合纈沙坦氫氯噻嗪治療原發(fā)性高血壓整體效果確切，可有效獲得血壓的穩(wěn)定控制及癥狀的明顯緩解，促進患者生活質(zhì)量的改善，值得臨床推廣應用。

Objective To explore the clinical efficacy of Xinxuening Tablets combined with valsartan and hydrochlorothiazide in treatment of essential hypertension. Methods A total of 116 patients with essential hypertension admitted to Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine from March 2021 to March 2022 were selected and divided into control group and treatment group according to random number table method, with 58 patients in each group. Patients in the control group were po administered with Valsartan and Hydrochlorothiazid Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Xinxuening Tablets on the basis of the control group, 4 tablets/time, three times daily. Both groups were treated for 12 weeks. The curative effect and the disappearance rate of main symptoms were observed in the two groups. The blood pressure (SBP), diastolic blood pressure (DBP), 24 h ambulatory blood pressure index, Duhenn Hypertension Quality of Life Scale and WHOQOL-BREF score were compared between two groups before and after treatment. Results After treatment, the total effective rate of treatment group was 96.55%, which was significantly higher than that of control group 86.21% (P＜0.05). After treatment, SBP and DBP in two groups were significantly decreased compared with before treatment (P＜ 0.05). After treatment, SBP and DBP in treatment group were lower than those in control group (P＜0.05). After treatment, 24 h SBP, 24 h DBP, daytime SBP (dSBP), daytime DBP (dDBP), night SBP (nSBP), night DBP (nDBP) 24 h mean arterial pressure (24 h MAP), 24 h SBP coefficient of variation (24 h SBPCV), 24 h variation coefficient of DBP (24 h DBPCV) was significantly decreased compared with that before treatment (P＜0.05). The decrease was more significant in treatment group (P＜0.05). After treatment, the disappearance rates of dizziness, dizziness, headache and chest distress in treatment group were 94.83%, 89.66% and 79.31%, respectively, which were significantly higher than 86.21%, 75.86% and 62.07% in control group (P＜ 0.05). After treatment, the Duhenna hypertension Quality of life scale score and WHOQOL-BREF score of both groups were significantly increased (P＜ 0.05), and after treatment, the Duhenna hypertension quality of life scale score and WHOQOL-BREF score of the treatment group were higher than those of control group (P＜0.05). Conclusion Xinxuening Tablets combined with valsartan and hydrochlorothiazide has a definite overall effect in treatment of essential hypertension, and can effectively obtain stable control of blood pressure and obvious relief of symptoms, promote the improvement of patients’ quality of life, which is worthy of clinical application.

R972

榆林市科技計劃項目（YF-2022-33）